Advances in Medicine (AIM) 2026

Early, long-term multimodal interventions are required to halt the progression of mild cognitive impairment (MCI) and Alzheimer’s disease, according to Professor Timothy Kwok of the Division of Geriatrics, Chinese University of Hong Kong (CUHK), who spoke at AIM 2026.

Donanemab administered for a limited duration continues to slow clinical progression in patients with early symptomatic Alzheimer’s disease (AD) over 3 years, according to Professor Chaur-Jong Hu of the Department of Neurology, Taipei Medical University, who spoke at Advances in Medicine (AIM) 2026.